Conditions: Non Small Cell Lung Carcinoma
Keywords: Carcinoma Non Small Cell Lung EGFR mutation Gefitinib
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 156
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate ORR (Objective Response Rate) of gefitinib as a second-line therapy for NSCLC patients based on RECIST (Response Evaluation Criteria in Solid Tumors Group) and check up ORR difference by EGFR mutation, gender, smoking history, and type of tumor.

Detailed description:

Arms:

Interventions: intervention 1: Gefitinib
Intervention descriptions: intervention 1: Gefitinib tablet 250mg once daily orally

Protocol document: